CIA
NBIX icon

Concurrent Investment Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Concurrent Investment Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$169K Buy
+1,000
New +$148K ﹤0.01% 1970

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Concurrent Investment Advisors's NBIX Position: Q2 2026 in Review

Concurrent Investment Advisors opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 748 shares worth $126K. The stake represents ﹤0.01% of the portfolio and ranks #2008 among its holdings. This is a return to the name: Concurrent Investment Advisors previously reported a position in NBIX as recently as Q1 2024.

Concurrent Investment Advisors first reported a position in NBIX in Q4 2023 and has held it in 3 quarters since. The position peaked at $332K in Q4 2023. 775 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Concurrent Investment Advisors held 748 shares of Neurocrine Biosciences worth $126K as of Q2 2026.
  • Neurocrine Biosciences was a new Concurrent Investment Advisors position in Q2 2026.
  • Neurocrine Biosciences made up ﹤0.01% of Concurrent Investment Advisors's portfolio in Q2 2026, its #2008 holding.
  • Concurrent Investment Advisors first reported a position in Neurocrine Biosciences in Q4 2023 and has held it in 3 quarters since.
  • Concurrent Investment Advisors's Neurocrine Biosciences position peaked at $332K in Q4 2023.
  • 775 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Concurrent Investment Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.